Bionoid Pharma Inc.
BINP
$0.08
$0.000.00%
OTC PK
| 03/31/2011 | |||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -69.45% | ||||
| Total Receivables | -- | ||||
| Inventory | -- | ||||
| Prepaid Expenses | -- | ||||
| Finance Division Loans and Leases Current | -- | ||||
| Total Finance Division Other Current Assets | -- | ||||
| Other Current Assets | -- | ||||
| Total Current Assets | -65.40% | ||||
|
|
|||||
| Total Current Assets | -65.40% | ||||
| Net Property, Plant & Equipment | -5.38% | ||||
| Long-term Investments | -- | ||||
| Goodwill | -- | ||||
| Total Other Intangibles | -2.57% | ||||
| Finance Div Loans & Leases LT | -- | ||||
| Total Finance Div Other LT Assets | -- | ||||
| Total Other Assets | -- | ||||
| Total Assets | -51.38% | ||||
|
|
|||||
| Total Accounts Payable | 21.52% | ||||
| Total Accrued Expenses | 1.59% | ||||
| Short-term Debt | -89.19% | ||||
| Current Portion of Long-Term Debt/Capital Leases | -- | ||||
| Finance Division Debt Current | 0.00% | ||||
| Total Finance Division Other Current Liabilities | -- | ||||
| Total Other Current Liabilities | -- | ||||
| Total Current Liabilities | -3.38% | ||||
|
|
|||||
| Total Current Liabilities | -3.38% | ||||
| Long-Term Debt | -- | ||||
| Short-term Debt | -89.19% | ||||
| Capital Leases | -- | ||||
| Finance Division Debt Non Current | -- | ||||
| Total Finance Division Other Non Current Liabilities | -- | ||||
| Total Other Liabilities | -- | ||||
| Total Liabilities | -3.38% | ||||
|
|
|||||
| Common Stock & APIC | 37.14% | ||||
| Retained Earnings | -38.71% | ||||
| Treasury Stock & Other | -81.80% | ||||
| Total Common Equity | -69.93% | ||||
|
|
|||||
| Preferred Stock Redeemable | -- | ||||
| Preferred Stock Non Redeemable | -- | ||||
| Preferred Stock Convertible | -- | ||||
| Preferred Stock, Others | -- | ||||
| Total Preferred Equity | -- | ||||
|
|
|||||
| Total Common Equity | -69.93% | ||||
| Total Preferred Equity | -- | ||||
| Total Minority Interest | -- | ||||
| Total Equity | -69.93% | ||||
|
|
|||||